Oct. 23 Financial Quick Takes: Alexion buyback; plus RAPT, NeuroRX and Oyster Point

Billion-dollar buyback for Alexion
The board of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) has approved a $1 billion share repurchase authorization, with no expiration date. Alexion announced the buyback with its 3Q19 earnings, in which it reported adjusted EPS of $2.79 on revenues of $1.26 billion, beating consensus estimates of $2.48 on $1.24 billion in revenues. Alexion also raised its full-year guidance for both EPS and revenue.

RAPT hops back in IPO queue
RAPT Therapeutics Inc. revived its IPO bid on Monday, filing to raise up to $92 million. The inflammatory disease company had delayed its listing in August after proposing to sell 5 million shares at $14-$16...